RNA Interference: A Promising Approach for the Treatment of HBV Infection

Hepatitis B virus (HBV) infection is global health problem with over 350 million HBV carriers worldwide and over one million deaths occurring annually due to HBV-induced liver diseases [1]. Currently, HBV infection is treated with immunomodulatory agents (e.g. IFN-α) and nucleoside analogs such as lamivudine which are only partially effective [2]. Drawbacks of current therapies include Low efficacy, severe side effects and occurrence of resistance due to HBV mutations [1,3]. In view of the aforementioned challenges posed by current treatment regimen, there is the need for a better treatments option that can suppress viral replication within short duration, have high cure rates and fewer side effects [3,4]. RNA interference (RNAi) is a process by which small interfering. RNA (siRNA) with specific sequences induce silencing of homologous genes by binding to their complementary mRNA and inducing the elimination of the mRNA [5]. RNAi has shown antiviral effect against HBV, Hepatitis C virus (HCV), Human Papillomavirus (HPV) and Human immunodeficiency virus (HIV) [5,6]. Unlike HCV and HIV, the small size genome and presence overlapping reading frames (ORFs) in HBV makes it more susceptible to inhibition by RNAi [2,7,8]. Abstract


Introduction
Hepatitis B virus (HBV) infection is global health problem with over 350 million HBV carriers worldwide and over one million deaths occurring annually due to HBV-induced liver diseases [1]. Currently, HBV infection is treated with immunomodulatory agents (e.g. IFN-α) and nucleoside analogs such as lamivudine which are only partially effective [2]. Drawbacks of current therapies include Low efficacy, severe side effects and occurrence of resistance due to HBV mutations [1,3]. In view of the aforementioned challenges posed by current treatment regimen, there is the need for a better treatments option that can suppress viral replication within short duration, have high cure rates and fewer side effects [3,4]. RNA interference (RNAi) is a process by which small interfering. RNA (siRNA) with specific sequences induce silencing of homologous genes by binding to their complementary mRNA and inducing the elimination of the mRNA [5]. RNAi has shown antiviral effect against HBV, Hepatitis C virus (HCV), Human Papillomavirus (HPV) and Human immunodeficiency virus (HIV) [5,6]. Unlike HCV and HIV, the small size genome and presence overlapping reading frames (ORFs) in HBV makes it more susceptible to inhibition by RNAi [2,7,8]. RNAi-based drugs can be expressed from introduced genes, they offer the possibility for a sustained therapeutic response [11]. siRNA mediated inhibition is specific and potent [3, 9,11] (Figure  1,2).

Methods of siRNA Synthesis
Chemical synthesis: This involves the production of sense and antisene strands, annealing of the strands, adding stable chemical entities and 2 nt overhangs at 3′ end.
Ambion (Huston, TX) recommended the following guidelines for designing siRNAs: Beginning with the AUG of the target gene transcript, search downstream for AA dinucleotide sequences, each AA and the 3′ adjacent 19 nt are potential siRNAs; blast the potential sequences against the species-specific genome database to eliminate cross-silencing phenomenon with nontarget genes [12]. a.
Web-based software called siDirect algorithm incorporated the Ambion guidelines above for designing siRNAs [3] b.
Endogenous vector Expression of Anti-HBV shRNA which involves the use of Plasmid to express shRNA that are converted into siRNA in cells [13,14].

b.
Cationic polymer: like liposome, also form complexes with the negatively charged phosphate groups of the siRNA e.g. NAG-MLP [17].

Challenges
Delivery of the siRNA into the target organ [3,10].
What has been done to address these hurdles...

ARC 520 Results
A single low dose of ARC-520 resulted in > 95% reduction of HBV RNA, proteins (eg.HBeAg and HBsAg) and viral DNA with long duration of effect in mouse and chimpanzee models of HBV infection ( Figure 5). In chimpanzee, Levels of HBV DNA, HBeAg , HBsAg only return to baseline after 43,43, and 71 days respectively of dosing ( Figure 5) [2]. ARC-520 has gone through phase-1-clinical trials. Results of a phase 1 from first-in-human safety and tolerability studies conducted among 36 patients with chronic HBV showed that the drug was reasonably safe and well tolerated. No dropouts for any reason and no serious adverse events [2].

Conclusion and Prospects for Clinical Application
The use of RNAi pathway as a new approach in antiviral drug discovery is promising as the genetic distance between mammalian and HBV genome represents an advantage in minimizing offtarget hits and reducing possible side effects [21]. The ability of RNAI to effectively and durably halt viral protein production can lead to complete HBsAg loss and conversion to seronegative status; eliminates long treatments and patient compliance issues [2]. Although, RNAi-based therapeutic intervention against HBV infection has shown to be promising, improvements in safety and efficacy of delivery methods however remained important objectives for future studies to adress [22][23][24][25][26][27].